UK-based epitaxial wafer and substrate provider IQE has reported that the overall market recovery is weaker than anticipated. As a result, the company expects its revenue for 2024 to remain flat compared to 2023. IQE also announced a strategic review of its assets, including the possibility of divesting its operations in Taiwan.